Physician profile
Ebone Powers
NPI 1306519848
$2,577.59
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,532 · 2023: $705 · 2024: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $677.26 | 2022-2024 | Farxiga, Airsupra, Tezspire |
| Abbvie INC. | $283.55 | 2022-2024 | |
| Lilly USA, LLC | $185.15 | 2022-2024 | Mounjaro, Jardiance |
| Genzyme Corporation | $178.87 | 2022-2023 | |
| Gilead Sciences, INC. | $130.58 | 2022 | |
| Grifols USA, LLC | $123.55 | 2022 | |
| Pulmonx Corporation | $122.68 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Novo Nordisk INC | $103.50 | 2022-2023 | |
| Insulet Corporation | $91.02 | 2023-2024 | Omnipod |
| Regeneron Healthcare Solutions, INC. | $89.81 | 2022 | |
| Inspire Medical Systems, INC. | $80.07 | 2023-2024 | Inspire |
| Glaxosmithkline, LLC. | $70.93 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $64.93 | 2022-2023 | |
| Amgen INC. | $53.78 | 2022-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.76 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $43.71 | 2022-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $42.55 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $22.54 | 2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.49 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.72 | 2024 | Voquezna |
| Pfizer INC. | $18.08 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.14 | 2022 | |
| Philips North America LLC | $16.90 | 2022 | |
| Exact Sciences Corporation | $16.87 | 2023 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $15.18 | 2022 | |
| Baxter Healthcare | $14.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.99 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebone Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.